Is AOD-9604 Legal in Pennsylvania?

What Is AOD-9604 and Why Does Its Classification Matter?

AOD-9604 is a synthetic fragment of human growth hormone (hGH), specifically the C-terminal amino acid sequence 176 to 191. Researchers at Monash University in Australia developed it in the 1990s with the hypothesis that this fragment retained the lipolytic properties of hGH without producing insulin-like growth factor-1 (IGF-1) elevation or the glucose-metabolism changes associated with full hGH. Its classification under U.S. Law determines whether a physician can legally prescribe it, whether a pharmacy can legally compound it, and whether a patient in Pennsylvania can legally possess it.

Why Classification Is Not Straightforward

The FDA classifies drugs along a spectrum that runs from approved new drugs through investigational new drugs (INDs) to unapproved substances. AOD-9604 does not fit cleanly into any single category. Metabolic Pharmaceuticals Ltd. Received Generally Recognized as Safe (GRAS) status from the FDA in 2014 for AOD-9604 as a food ingredient under GRAS Notice No. GRN 000400, but GRAS designation for a food ingredient is legally distinct from approval as a drug. View the GRAS docket on the FDA website.

That GRAS notice does not authorize AOD-9604 for use as an injectable peptide drug. The FDA evaluates injectable peptides under its drug approval framework, not its food-additive framework.

Phase 2 and 3 Clinical Evidence

Metabolic Pharmaceuticals conducted a series of trials in the early 2000s. The Phase 2b trial enrolled 300 obese subjects across 24 weeks and showed modest but statistically detectable reductions in body fat at doses of 1 mg/day oral AOD-9604. The Phase 3 trial, however, did not meet its primary endpoint for weight loss, and the company did not pursue FDA approval. Published mechanistic data on the hGH fragment 176-191 and fat metabolism is indexed at PubMed. That 2001 paper by Heffernan et al. In the Journal of Endocrinology demonstrated lipolytic activity in rodent models, but human trial outcomes diverged from animal predictions.

No large randomized controlled trial of injectable AOD-9604 in humans has reached peer-reviewed publication with sufficient sample size to establish efficacy in the FDA sense. That absence of an approved New Drug Application (NDA) is the single most important legal fact about AOD-9604 in every U.S. State, including Pennsylvania.

Federal Regulatory Framework: The Foundation for Pennsylvania Law

Pennsylvania does not maintain a separate peptide-specific statute that addresses AOD-9604 by name. The state's legal framework for prescription drugs and compounding defaults to federal law as its foundation. Understanding federal rules is therefore step one for any Pennsylvania patient or prescriber.

FDA Approval Status

AOD-9604 has no approved NDA or Biologics License Application (BLA) on file with the FDA. You can confirm this by searching the FDA's Drugs@FDA database, which returns no results for "AOD-9604." Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), marketing or distributing an unapproved new drug in interstate commerce is prohibited. The FDA's overview of unapproved drugs is accessible here.

This matters for Pennsylvania residents because virtually all compounding pharmacies source their active pharmaceutical ingredients (APIs) through interstate channels. A pharmacy in Philadelphia purchasing AOD-9604 bulk powder from a supplier in another state is participating in interstate commerce, which places the transaction squarely within FDA jurisdiction.

The 503A and 503B Compounding Distinctions

The Drug Quality and Security Act of 2013 created two distinct compounding categories under Sections 503A and 503B of the FD&C Act, and each carries different legal permissions and restrictions. The FDA's summary of both sections is published here.

Section 503A covers traditional compounding pharmacies that prepare medications for individual patients based on a valid prescription from a licensed practitioner. These pharmacies may compound drugs from bulk APIs only if the substance appears on the FDA's 503A bulks list, is a component of an FDA-approved drug, or meets other specific criteria. AOD-9604 is not currently on the FDA's positive 503A bulks list. The FDA published its most recent interim policy on peptide compounding in 2023 and 2024, indicating that certain peptides not on approved lists face heightened scrutiny. FDA's interim guidance on compounded drug products is at this link.

Section 503B outsourcing facilities operate at larger scale and without patient-specific prescriptions. They may only use APIs on the FDA's approved 503B bulks list. AOD-9604 does not appear on that list either. A 503B facility compounding and distributing AOD-9604 would be operating outside the statute's permissions.

DEA Schedule Status

AOD-9604 is not listed under any schedule of the Controlled Substances Act (CSA). The DEA's list of scheduled substances is searchable here. This means possession of AOD-9604 does not carry the criminal penalties associated with Schedule II drugs like testosterone or Schedule III substances like certain anabolic steroids. The absence of DEA scheduling does not, however, make AOD-9604 legal to obtain without a prescription or to manufacture without FDA oversight.

Pennsylvania State Law: What the Commonwealth Adds

Pennsylvania's Pharmacy Act (63 P.S. § 390-1 et seq.) governs pharmacy practice in the Commonwealth and requires pharmacists to operate consistent with federal law. The Pennsylvania State Board of Pharmacy has not published a specific bulletin addressing AOD-9604 or peptide compounds as a class. No Pennsylvania statute names AOD-9604 as a controlled or prohibited substance.

Pennsylvania Medical Practice Act

The Pennsylvania Medical Practice Act of 1985 (63 P.S. § 422.1 et seq.) governs physician prescribing. A licensed Pennsylvania physician may prescribe any drug, including off-label uses of approved drugs and compounded preparations, within the scope of their clinical judgment, provided the prescription is for a legitimate medical purpose and the drug can be lawfully dispensed. The phrase "lawfully dispensed" is the critical filter. Because the federal compounding framework restricts AOD-9604 as described above, a prescription written in Pennsylvania does not automatically create a lawful dispensing pathway.

The Gray Zone in Practice

In practice, a meaningful number of compounding pharmacies, particularly those operating under 503A, do fill AOD-9604 prescriptions today. Their legal argument typically rests on the claim that AOD-9604 is not explicitly prohibited and that the FDA's enforcement discretion has not targeted small-volume 503A compounders for this specific peptide. That argument carries real legal risk. The FDA's 2023 and 2024 guidance documents signaled increasing scrutiny of peptide compounds lacking approved status. FDA's 2024 statement on bulk drug substances for compounding is available here.

Pennsylvania patients who obtain AOD-9604 through a compounding pharmacy today are doing so through a pathway that the FDA has not affirmatively authorized. That is distinct from saying it is criminally illegal for the patient, but it does mean the pharmacy itself faces compliance risk that could disrupt supply.

How to Get AOD-9604 in Pennsylvania Legally

The phrase "legally" requires precision here. No path to injectable AOD-9604 in Pennsylvania is risk-free given the current regulatory status, but some paths carry substantially lower legal risk than others.

The Three-Part Compliance Framework

Any Pennsylvania patient seeking AOD-9604 should evaluate their access pathway against three criteria before proceeding.

First: a valid prescription from a licensed Pennsylvania physician. Self-administering a peptide obtained without a prescription, from an overseas supplier, or from a research-chemical vendor carries both health risks and potential legal exposure under the FD&C Act's prohibition on receiving unapproved new drugs. Telehealth platforms licensed to practice in Pennsylvania can issue prescriptions for AOD-9604 if the prescriber determines clinical appropriateness and documents that judgment.

Second: a licensed 503A compounding pharmacy that can demonstrate compliance with current FDA guidance. Before filling a prescription, ask the pharmacy whether it operates under an FDA-registered facility number, whether its AOD-9604 API supplier holds a Drug Master File (DMF) with the FDA, and whether it has received any FDA warning letters. A pharmacy that cannot answer those questions is a pharmacy to avoid.

Third: sourcing only from domestic licensed pharmacies. Imported peptides purchased from overseas vendors operate entirely outside the FDA's oversight framework. They may be counterfeit, mislabeled, or microbiologically contaminated. A 2018 study published in JAMA Internal Medicine found that 87% of drug products sampled from illegal online pharmacies failed quality standards. The JAMA Internal Medicine data is cited here.

Telehealth Prescribers in Pennsylvania

Pennsylvania law allows telemedicine prescribing under Act 10 of 2021, provided the prescriber has established a valid patient-provider relationship and the prescription meets all standard requirements. Some telehealth hormone and peptide clinics licensed in Pennsylvania include AOD-9604 consultations in their service menus. Patients should verify that the telehealth provider holds an active Pennsylvania medical license, which can be confirmed through the Pennsylvania Department of State license lookup tool.

Research-Use Purchases

AOD-9604 is available from domestic chemical suppliers labeled "for research use only, not for human use." Purchasing such material for personal injection is a violation of the label, constitutes obtaining an unapproved new drug for human use, and removes any quality assurance the compounding pharmacy framework would otherwise provide. This pathway is not recommended.

Safety Profile: What the Clinical Record Actually Shows

No regulatory discussion of AOD-9604 in Pennsylvania is complete without a realistic summary of what the safety data shows.

Animal and Mechanistic Data

The 2001 Heffernan et al. Paper referenced above demonstrated that hGH fragment 176-191 stimulated lipolysis in rat adipocytes at concentrations achievable with subcutaneous injection, without the IGF-1 elevation seen with full hGH. That PubMed-indexed paper is linked here. A 2004 study by Ng et al. In Growth Hormone and IGF Research replicated the lipolytic findings in obese rodent models and found no statistically significant changes in bone density at doses equivalent to clinical ranges. The Ng et al. Study is indexed at PubMed here.

Human Safety Signals

The Metabolic Pharmaceuticals Phase 2b oral AOD-9604 trial reported adverse events comparable to placebo across 24 weeks in 300 subjects, with no serious adverse events attributed to the drug. The injectable form has a much thinner human safety dataset. No peer-reviewed phase 2 trial of injectable AOD-9604 in humans has been published with sufficient statistical power to characterize rare adverse events. That data gap is not evidence of safety. It is evidence of an incomplete record.

Absence of Endocrine Suppression

One frequently cited advantage of AOD-9604 over full hGH is that the fragment does not appear to suppress the hypothalamic-pituitary-somatotropic axis in the way exogenous hGH does. A review of hGH axis regulation and fragment peptides is available through the NIH here. This theoretical advantage drives much of the clinical interest in AOD-9604 for body composition support, but it remains a theoretical advantage in the absence of long-term human trials measuring axis suppression directly.

What Prescribers in Pennsylvania Need to Know

A Pennsylvania physician who prescribes AOD-9604 should document the following in the patient chart to satisfy both the Medical Practice Act and standard-of-care expectations.

Documentation Requirements

The chart should contain a clear clinical indication, a summary of the available evidence including its limitations, a discussion of the lack of FDA approval, patient acknowledgment of the off-label and partially experimental nature of the treatment, and the name and license number of the compounding pharmacy filling the prescription. The Endocrine Society's clinical practice guidelines on growth hormone use, while not addressing AOD-9604 directly, establish a documentation standard for off-label peptide therapies that Pennsylvania physicians can adapt. The Endocrine Society's 2011 GH guidelines are available at the Journal of Clinical Endocrinology and Metabolism here.

Prescriber Liability

A physician who prescribes AOD-9604 through a non-compliant compounding pharmacy, or who fails to document informed consent for an unapproved therapy, faces potential Medical Practice Act violations. Pennsylvania's Bureau of Professional and Occupational Affairs handles complaints against licensed physicians. That risk is manageable with proper documentation but is not zero.

Comparing AOD-9604 to Approved Alternatives in Pennsylvania

Patients and prescribers evaluating AOD-9604 for fat metabolism should compare it against approved options with established evidence bases.

Semaglutide 2.4 mg (Wegovy), approved by the FDA in June 2021 for chronic weight management, produced a mean 14.9% reduction in body weight at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% with placebo (P<0.001). The STEP-1 results were published in the New England Journal of Medicine here. Tirzepatide 15 mg (Zepbound), approved in November 2023, produced a mean 20.9% reduction in body weight at 72 weeks in the SURMOUNT-1 trial (N=2,539). The SURMOUNT-1 data are published in the New England Journal of Medicine here.

AOD-9604 has no comparable human trial data establishing a specific mean weight-loss percentage at a defined dose over a defined duration. Prescribers who frame AOD-9604 as an adjunct to lifestyle modification, rather than a primary weight-loss agent, are working within a more defensible clinical rationale.

The American Association of Clinical Endocrinology's 2023 clinical practice guidelines on obesity state that pharmacotherapy should be considered for patients with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity, and prioritize agents with strong efficacy and safety data. The AACE 2023 obesity guidelines are available at aace.com here. AOD-9604 does not appear in those guidelines.

Current FDA Enforcement Trends and What They Mean for Pennsylvania

The FDA has issued warning letters to compounding pharmacies over specific peptides, most publicly including BPC-157 and TB-500 in 2023 and 2024, citing their unapproved status and absence from the 503A/503B bulks lists. AOD-9604 has not received a named warning letter as of the date of this article's review, but the directional trend is clear. FDA's compounding enforcement actions are listed here.

The FDA's February 2024 interim policy update on bulk drug substances noted that substances not on any approved list and lacking an IND face the highest regulatory scrutiny when compounded for human use. Pennsylvania compounding pharmacies that continue to fill AOD-9604 prescriptions are operating with awareness of that risk; patients should be aware of it too.